Regeneron Pharmaceuticals Investor Presentation — June 2021

Document content

Oncology Investor Event ASCO 2021

JUNE 2021This presentation includes forward -looking statements that involve risks and uncertainties relating tofuture events and thefuture performance ofRegeneron Pharmaceuticals, Inc.

(“Regeneron” orthe“Company”), andactual events orresults may differ materially from these forward- looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,”

“seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notallforward- looking statements contain these

identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS- CoV-2(thevirus thathascaused theCOVID -19pandemic) on

Regeneron's business anditsemployees, collaborators, andsuppliers andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators’ ability tocontinue toconduct

research andclinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise commercialized byRegeneron and/or itscollaborators

(collectively, "Regeneron’s Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andproduct candidates

being developed byRegeneron and/or itscollaborators (collectively, “Regeneron’s Product Candidates”) andresearch andclinical programs now underway orplanned, including without

limitation Libtayo® (cemiplimab) asmonotherapy orincombination with other ofRegeneron’s Product Candidates discussed inthis presentation, including fianlimab (REGN3767),

Regeneron’s and itscollaborators’ other oncology programs (including odronextamab (REGN1979 ),REGN5458, REGN 5459, REGN5093, and REGN 5093- M114), Regeneron’s and its

collaborators’ other hematology programs, Regeneron’s anditscollaborators’ earlier -stage programs, andtheuseofhuman genetics inRegeneron’s research programs ;safety issues

resulting from theadministration ofRegeneron’s Products andRegeneron’s Product Candidates inpatients, including serious complications orside effects inconnection with theuseof

Regeneron’s Products andRegeneron’s Product Candidates inclinical trials ;thelikelihood, timing, andscope ofpossible regulatory approval andcommercial launch ofRegeneron’s Product

Candidates andnew indications forRegeneron’s Products, including without limitation those listed above; thepossible success ofRegeneron’s oncology strategy andthelikelihood and

timing ofachieving anyoftheanticipated milestones described inthispresentation; theextent towhich theresults from theresearch anddevelopment programs conducted byRegeneron

and/or itscollaborators may bereplicated inother studies and/or lead toadvancement ofproduct candidates toclinical trials, therapeutic applications, orregulatory approval ;ongoing